Kobayashi Pharmaceutical Co., Ltd. (4967.T)
JPY 5942.0
(-0.05%)
JPY 5942.0
(-0.05%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 18.36 Billion | 31.91 Billion | 22.41 Billion | 23.98 Billion | 20.08 Billion | 20 Billion |
| Net Income | 20.33 Billion | 27.95 Billion | 27.63 Billion | 26.63 Billion | 26.8 Billion | 25.3 Billion |
| Depreciation & Amortization | 6.05 Billion | 5.35 Billion | 4.83 Billion | 4.1 Billion | 4.12 Billion | 3.4 Billion |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -6.57 Billion | 6.83 Billion | -2.14 Billion | -1.28 Billion | -4.27 Billion | -3.69 Billion |
| Other non-cash items | -1.45 Billion | -8.22 Billion | -7.9 Billion | -5.47 Billion | -6.56 Billion | -5 Billion |
| Investing Cash Flow | -19.57 Billion | -14.31 Billion | 7.99 Billion | -12.65 Billion | -5.07 Billion | -8.06 Billion |
| Investments in PPE | -13.56 Billion | -16.22 Billion | -4.18 Billion | -4.14 Billion | -4.8 Billion | -3.7 Billion |
| Acquisitions | -11.17 Billion | 3 Million | 200 Million | -11.35 Billion | -161 Million | -2.46 Billion |
| Investment purchases | -49.35 Billion | -49.58 Billion | -49.46 Billion | -57.89 Billion | -53.06 Billion | -55.31 Billion |
| Sales/Maturities of investments | 54.74 Billion | 51.75 Billion | 61.56 Billion | 60.72 Billion | 53.3 Billion | 53.54 Billion |
| Other Investing Activities | -231 Million | -254 Million | -119 Million | 10 Million | -348 Million | -132 Million |
| Financing Cash Flow | -19.46 Billion | -20.75 Billion | -10.37 Billion | -6.01 Billion | -14.58 Billion | -4.28 Billion |
| Debt repayment | - | -1 Million | -12 Million | -5 Million | -570 Million | -1 Million |
| Dividends payments | -7.22 Billion | -6.5 Billion | -6.25 Billion | -5.78 Billion | -5.33 Billion | -4.81 Billion |
| Common Stock Repurchased | -12 Billion | -14.05 Billion | -3.94 Billion | - | -8.01 Billion | - |
| Common Stock Issuance | - | 1 Million | 12 Million | - | -662 Million | 361 Million |
| Other Financing Activities | -240 Million | -194 Million | -183 Million | -230 Million | -2 Million | 173 Million |
| Accounts receivables | -3.78 Billion | 8.29 Billion | -1.52 Billion | 1.58 Billion | -1.42 Billion | -3.36 Billion |
| Accounts payables | -1.39 Billion | 1.24 Billion | 813 Million | -984 Million | -993 Million | 481 Million |
| Inventory | -3.17 Billion | -1.97 Billion | -462 Million | 1.3 Billion | -1.02 Billion | -493 Million |
| Other working capital | 1.76 Billion | -725 Million | -971 Million | -3.19 Billion | -838 Million | -3.2 Billion |
| Cash at beginning of period | 73.18 Billion | 81.98 Billion | 61.15 Billion | 56.27 Billion | 55.91 Billion | 48.68 Billion |
| Cash at end of period | 71.53 Billion | 79.48 Billion | 81.98 Billion | 61.15 Billion | 56.27 Billion | 55.91 Billion |
| Capital Expenditure | -13.56 Billion | -16.22 Billion | -4.18 Billion | -4.14 Billion | -4.8 Billion | -3.7 Billion |
| Effect of forex changes on cash | 890 Million | 673 Million | 797 Million | -425 Million | -79 Million | -431 Million |
| Net cash flow / Change in cash | -1.64 Billion | -2.5 Billion | 20.83 Billion | 4.88 Billion | 356 Million | 7.22 Billion |
| Free Cash Flow | 4.79 Billion | 15.68 Billion | 18.23 Billion | 19.83 Billion | 15.28 Billion | 16.3 Billion |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 460 Million | 976 Million | 4.84 Billion | 20.33 Billion | 7.63 Billion | 4.25 Billion |
| Depreciation & Amortization | - | - | 1.76 Billion | 6.05 Billion | 1.5 Billion | 1.4 Billion |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | - | -6.57 Billion | - | - |
| Other non-cash items | -460 Million | -976 Million | -4.84 Billion | -1.45 Billion | -7.63 Billion | -4.25 Billion |
| Investing Cash Flow | - | - | - | -19.57 Billion | - | - |
| Investments in PPE | - | - | - | -13.56 Billion | - | - |
| Acquisitions | - | - | - | -11.17 Billion | - | - |
| Investment purchases | - | - | - | -49.35 Billion | - | - |
| Sales/Maturities of investments | - | - | - | 54.74 Billion | - | - |
| Other Investing Activities | - | - | - | -231 Million | - | - |
| Financing Cash Flow | - | - | - | -19.46 Billion | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | -7.22 Billion | - | - |
| Common Stock Repurchased | - | - | - | -12 Billion | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | -240 Million | - | - |
| Accounts receivables | - | - | - | -3.78 Billion | - | - |
| Accounts payables | - | - | - | -1.39 Billion | - | - |
| Inventory | - | - | - | -3.17 Billion | - | - |
| Other working capital | - | - | - | 1.76 Billion | - | - |
| Cash at beginning of period | - | - | 87.18 Billion | 73.18 Billion | 91.18 Billion | 92.98 Billion |
| Cash at end of period | - | - | 71.53 Billion | 71.53 Billion | 87.18 Billion | 91.18 Billion |
| Capital Expenditure | - | - | - | -13.56 Billion | - | - |
| Effect of forex changes on cash | - | - | - | 890 Million | - | - |
| Net cash flow / Change in cash | - | - | -15.64 Billion | -1.64 Billion | -4 Billion | -1.8 Billion |
| Free Cash Flow | - | - | 3.53 Billion | 4.79 Billion | 3 Billion | 2.8 Billion |
005430
1909
FGEN
CASP
9304
002478